The presence of brain metastases occurring in breast cancer patients is relatively common, noted in 30% of patients in autopsy studies ([@bib62]) and being clinically apparent in up to 16% of metastatic breast cancer patients ([@bib8]). This, along with limited treatment options, can cause significant morbidity and result in a dismal prognosis.

Previous studies have demonstrated certain characteristics of primary breast cancers that make the development of brain metastases more likely, such as being diagnosed at a young age, breast tumours being hormone receptor negative, \>2 cm in diameter, node positive, grade 3 and HER2 positive ([@bib30]; [@bib2]; [@bib57]). In spite of the development of HER2-targeted therapies such as trastuzumab, HER2-positive metastatic breast cancer patients continue to have a high incidence of brain metastases (25--37%) because of improving extracranial control of disease, inability of treatments to access or be active in the central nervous system (CNS) or a natural predilection for such tumours to deposit in the CNS ([@bib9]; [@bib56]). Increasing use of and improvements in adjuvant cytotoxic chemotherapy also appear to be altering the pattern of metastatic relapse, with fewer relapses overall but a relative increase in non-bone metastases ([@bib69]). It would therefore appear that brain metastases from breast cancer will continue to be a significant clinical problem for some time to come.

The degree to which a biopsy to confirm metastatic disease is required is debated ([@bib1]). However, it is becoming increasingly recognised that there are molecular changes to extracranial breast cancer metastases that could make a difference to treatment, such as the metastatic tumours having a change of HER2 positivity 24%--48% of the time and a 7--13% fall in oestrogen receptor (ER)- or progesterone receptor (PR)-positive metastatic tumours ([@bib53]; [@bib46]; [@bib45]). Prospective analysis of primary and recurrent breast cancer confirmed changes in ER (10%), PR (25%) and HER2 (3%) ([@bib61]). However, very little is known about brain metastases and whether they differ at a molecular level to the breast primary and therefore whether an alternative treatment strategy may be indicated.

Published studies that have analysed the molecular profile of breast cancer brain metastases have had small numbers and shown mixed results, tested a limited panel of targets or had variable clinical outcome information. In matched breast and brain sample studies, results have shown development of HER2 amplification in 2 out of 23 cases tested in brain metastases and an excess of epidermal growth factor receptor (EGFR) in the brain metastases (41% *vs* 16%) ([@bib18]). In a study with 43 patients, there was no significant change in ER, PR or HER2 in tissue from the breast and secondary brain malignancy ([@bib28]), whereas a change was demonstrated in brain metastases for ER, PR or HER2 in 7 out of 24 patients ([@bib70]). Testing HER2 alone in 75 matched patient samples, there was a significant rise in brain metastases compared with the breast primary ([@bib15]). Contrary to this, in sample studies of 24 and 21 matched patients, there was a less significant change in HER2, but an apparent loss of ER/PR positivity in brain metastases ([@bib3], [@bib4]). This pattern of loss of hormone receptors but a more stable HER2 pattern in CNS tissue was also demonstrated in a study with 120 patients ([@bib14]).

The small size of many of these studies limits statistical power and they have demonstrated contrasting results. There is also developing research and clinical interest in growth pathways beyond ER, PR and HER2 and mechanisms of resistance to current treatments. The fact that CNS metastases are so difficult to access for histology gives an opportunity to add evidence through analysis of the changing patterns of traditional targets in breast primaries and their corresponding brain metastases. Furthermore, their poor prognosis gives impetus to investigate alternative pathways for which there is a paucity of data that could be aberrant and demonstrate further loss of stability of the original breast cancer. If there are significant changes, these may aid prognostication or targeting of drug development and treatment.

There have been huge developments in the understanding of the complexity of breast cancer. Genomic study has recognised aberrant genes that can be useful in predicting prognosis, such as the Oncotype DX 21 gene score ([@bib48]) or in combination with clinical factors in the Endopredict score ([@bib17]). The identification of specific genomic alterations has enabled grouping of breast cancer into the different intrinsic subtypes of luminal A, luminal B, HER2, basal and normal ([@bib49]) with their varying clinical characteristics and prognoses that can aid therapy decisions.

Within these groupings it is increasingly recognised that there is still much diversity. Multiple drivers for malignancy can occur in a range of cellular control pathways, such as cell cycle regulation, AKT signalling, chromatin function, DNA damage, apoptosis and repair, MAPK signalling, tissue organisation and transcription regulation. The degree of diversity in these breast pathways within breast cancer can be variable and extensive ([@bib68]).

Perhaps because of the difficulty in accessing suitable material for analysis, very little is known about the genomics of breast cancer brain metastases. [@bib55] performed deep genomic profiling of 35 unmatched brain metastases and identified multiple chromosomal gains and deletions, amplified and deleted genes, enriched cell cycle pathways and defects in cell migration, adhesion and permeability. There is concern that this novel biology is not thoroughly understood, may not be targetable and is heterogeneous with the prospect of molecular evolution and resistance ([@bib60]). With these multiple abnormalities, the challenge is to establish the clinically valuable mutations that drive carcinogenesis and metastasis and separate from the bystander background mutations ([@bib21]).

Because of this uncertainty regarding the primacy of the multiple genetic abnormalities and their potential clinical utility, we selected for analysis factors that are established therapeutic targets, had clinical data with links to a poor prognosis or putative roles in metastasis development or therapy resistance.

Oestrogen receptor, PR and HER2 were selected to be analysed as they are current prognostic and therapeutic targets. The p27kip1 is a negative regulator of cell proliferation, with upregulation inhibiting the invasion of breast cancer cells ([@bib41]). It can affect hormone receptor levels and sensitivity, with low nuclear expression in ER-negative PR-negative small breast cancers ([@bib40]), but upregulation causing antioestrogen insensitivity ([@bib71]). It may also affect chemosensitivity, with reduced expression of p27kip1 being associated with poor outcomes with CMF chemotherapy ([@bib23]) and with links to trastuzumab resistance ([@bib43]). Conversely, in node-negative cases, high expression detected by immunohistochemistry indicated a poor prognosis ([@bib7]) but subsequent meta-analysis indicated reduced p27kip1 as an independent prognostic factor for poor overall survival ([@bib22]).

Cyclin D1 is a protein that regulates cell cycle progression during the G1/S-phase transition and when overexpressed can reduce mean generation time of human mammary epithelial cells, contributing to their malignant potential ([@bib29]). It appears to promote cell migration as a collaborative oncogene with p27kip1 ([@bib35]). Overexpression of cyclin D1 as expressed by immunohistochemistry has been associated with early relapse and poor prognosis, particularly for ER-positive breast cancers ([@bib65]), but with relatively longer survival once metastases have developed ([@bib13]). An association with favourable prognostic factors in breast cancer has been noted ([@bib16]).

Epidermal growth factor receptor is a transmembrane receptor for members of the epidermal growth factor family, triggering cell proliferation. High EGFR has been associated with a poor prognosis in breast cancer ([@bib34]) and linked to the development of breast cancer brain metastasis ([@bib25]), with roles in cell migration and invasion promoting brain metastasis ([@bib44]). EGFR positive breast cancer appears more commonly in patients with poorer prognosis grade 3 disease and oestrogen receptor negative tumours ([@bib58]). Increased signalling of EGFR has also been associated with trastuzumab resistance ([@bib19]).

Insulin-like growth factor 1 (IGF1) binding to insulin-like growth factor 1 receptor (IGF1R) triggers a signalling cascade that leads to cellular proliferation and antiapoptosis, indicating a potentially significant role in breast cancer progression and metastasis ([@bib39]; [@bib12]). [@bib10] discovered significantly higher levels of IGF1R in breast cancer stem cells compared with non-breast cancer stem cells and proposed it as an attractive target for therapy. Indeed, when IGF1R was suppressed, growth of breast cancer cells and metastasis was reduced ([@bib66]). Furthermore, in a cell line with a tendency to brain metastasis, high levels of IGF1R were detected ([@bib47]) and, when suppressed, IGF1R inhibition attenuates the development of breast cancer brain metastasis ([@bib54]). Both IGF1 and IGF1R appear to have a role in prognosis ([@bib5]) and evidence also suggests a role for IGF1R in trastuzumab resistance ([@bib19]) and IGF1 in resistance to tamoxifen ([@bib11]).

Vascular endothelial growth factor A (VEGFA) binds to vascular endothelial growth factor receptor 2 (VEGFR2) that appears to mediate many of the known responses to VEGF including angiogenesis, increased vascular permeability, cell migration, invasion and inhibition of apoptosis ([@bib42]; [@bib51]). In breast cancer, VEGFA expression as measured by immunohistochemistry ([@bib59]) was significantly higher in primary *vs* metastatic breast cancer, with higher levels also being associated with low cell proliferation ([@bib36]). Vascular endothelial growth factor A expression has however been implicated in promoting growth of breast cancer metastases ([@bib31]). When VEGFR2 is inhibited, angiogenesis and tumour growth is also inhibited ([@bib67]) and it is associated with a worse outcome in breast cancer ([@bib20]). In terms of impact on therapy, high levels of VEGFA are associated with greater treatment effect for chemotherapy with bevacizumab ([@bib38]), but conversely may reduce tamoxifen ([@bib52]) and radiotherapy efficacy ([@bib37]). One possible explanation for the high incidence of brain metastases in HER2-positive breast cancer is resistance to HER2-targeted therapies in the brain and there are early data that VEGFR2 blockade may overcome this resistance ([@bib32]).

Transforming growth factor-*β* (TGF*β*) regulates cell proliferation, differentiation, migration and apoptosis ([@bib27]). It promotes metastasis in cancer cells ([@bib50]) and when blocked it appears to inhibit breast cancer cell invasiveness ([@bib64]). It has potential roles in prognosis, being associated with more aggressive tumours likely to metastasise and reduced survival ([@bib5]), with trastuzumab resistance ([@bib6]) and failure through tamoxifen ([@bib63]. [@bib5] commented on the promising candidacy of TGF*β* for targeted therapy, along with IGF1/IGF1R and VEGFA.

Aims and Objectives
===================

The aim of this study was to measure ER, PR, HER2 expression, IGF1 and IGF1R, VEGFA, VEGFR2, EGFR, TGF*β*, p27kip1 and cyclin D1 in the primary breast tumour and recurrent tumour in the brain metastasis to quantify the percentage of tumours that have changed their status. The impact of any changes on survival of the patients was also investigated.

Materials and methods
=====================

Patients with resected brain metastases from 1990 to 2011 were identified from a regional electronic database and multidisciplinary team (MDT) meeting records. Clinical data were collected from hospital notes and information gathered on age, number of brain metastases, disease-free interval and overall survival and primary tumour characteristics including size, grade, nodal status and treatments received.

Patients were deemed eligible if histological samples were available from primary invasive carcinoma of the breast and resected (or biopsies from) brain metastases of the same histological type. They were excluded if there was insufficient tissue available from either the breast or the brain malignant process.

Immunohistochemistry (IHC) with tissue microarray analyses and fluorescence *in situ* hybridisation (FISH) were performed on formalin-fixed paraffin-embedded archive tissue from primary breast tumours and matched brain metastases from the same patients. Anonymised histological and IHC evaluation was performed by a consultant pathologist using a multi-headed light microscope (Olympus BX51, Tokyo, Japan). Three cores for each tumour were evaluated, the scores were tabulated and an average result calculated.

The expression levels of the relevant biomarkers were determined using a subjective composite score based on the evaluation of intensity and percentage of cells exhibiting nuclear or nuclear and/or cytoplasmic staining. An Allred score of ⩾3 was determined to be positive for ER and PR, with 3+ HER2 scored positive. Specimens that were reported to have a 2+ borderline result for HER2 were subsequently analysed for overexpression using FISH. A score of ⩾3 was also deemed positive for IGF1, IGF1R, VEGFA, VEGFR2, EGFR, TGF*β*, p27kip1 and cyclin D1, but as there is less consistent information regarding levels of staining deemed to be positive or negative for non-ER, -PR and -HER2 molecules and their corresponding clinical relevance, any degree of change was also reviewed.

Statistical analysis was performed using SPSS Version 19 for Windows software (Statistical Package for the Social Sciences, SPSS Inc., Chicago, IL, USA). Categorical and continuous variables were described using mean (s.d.), median (IQR) or counts (%) as appropriate. The Kaplan--Meier method was used for survival analysis. Levels of expression in the breast primary and resected brain metastases from each patient were analysed using paired/independent *t*-tests or the nonparametric equivalent Pearson\'s correlation (two tailed) test to analyse the relationship of survival outcomes and time to brain metastases. Impact of a positive score for the biomarkers on the time from brain metastasis to death was reviewed with the Mann--Whitney test. Statistical significance was accepted if *P*\<0.05.

Ethical approval was given by South West 1 Research Ethics Committee of the National Research Ethics Service, REC reference 10/H0203/30.

Results
=======

A total of 41 patients were identified and eligible for the study. The mean (s.d.) age of the patients was 50.7 (12.4) years, with a median (IQR) 26 (25)-month interval between breast cancer diagnosis and development of brain metastases. The range of time from breast cancer diagnosis to brain metastasis varied considerably, with one patient presenting with CNS metastases with an occult breast primary, whereas the longest duration was 244 months after the original breast diagnosis. Median (IQR) time from brain metastasis diagnosis to death was 15 (23) months, with the median times for survival from the diagnosis of brain metastases in relation to the tested molecules displayed in [Table 1](#tbl1){ref-type="table"}. There was a \>12-month superior survival relative to the contrary tumour readings if the brain lesion was positive for ER or PR and if negative for IGF1R.

A total of 13 patients (32%) had a HER2-positive breast primary, with 12 receiving HER2-directed therapy before development of brain metastases. At initial diagnosis, 15 patients (37%) had an ER-positive breast cancer. A total of 11 patients underwent biopsy of their brain secondary, 30 more extensive surgical resection, with median survival 7 months for the biopsied group and 16 months for the resected. In all, 28 patients received whole-brain radiotherapy (WBRT), 1 patient stereotactic radiotherapy (SRT) alone, 6 patients both WBRT and SRT and 6 did not have radiotherapy information available. In the irradiated group, those receiving stereotactic radiotherapy with or without WBRT had superior outcomes, with median survival 43 months as opposed to 11 months. The clinical details and outcomes are described further in [Table 2](#tbl2){ref-type="table"}.

Overall, there were only 3 patients (7%) who had no change in comparing the breast primary and brain secondary from positive to negative or negative to positive for at least one of the tested molecules. An example of a change in the characteristic tested is seen in [Figure 1](#fig1){ref-type="fig"}.

Specific levels of positive findings in the breast primary and brain secondary with changes in the molecular profile of the breast lesion compared with the brain secondary are illustrated in [Table 3](#tbl3){ref-type="table"}.

There was a change in \>10% of the 41 patients from a positive breast primary to a negative brain secondary for p27kip1 and from a negative breast cancer to a positive brain metastasis for HER2, EGFR, IGF1, cyclin D1 and p27kip1. When considering the proportion of tumours that changed where four or more were initially positive or negative, it is notable that over half with an originally negative breast cancer turned positive in their brain metastases for IGF1, IGF1R, p27kip1 and cyclin D1.

There were statistically significant rises in the brain metastases for p27kip1 (*P*=0.023) and cyclin D1 (*P*=0.030). Within the brain metastases, VEGFA demonstrated a significant fall in levels (*P*=0.012), although when considering a level of 3 for staining as positive, there was no change between the breast primary and brain secondary, and degree of change for VEGFA was small, with no breast or brain samples scoring over 2 on immunohistochemistry. Analysis of these alterations from 'negative\' in the breast to 'positive\' or vice versa in the brain sample and their influence on prognosis demonstrated that they did not have a significant impact on the time from brain metastasis to death. There was also no statistically significant influence on survival duration from brain metastasis for clinical factors, such as extent of surgery or radiotherapy.

When analysing the individual characteristics of the brain metastasis and impact on survival from their diagnosis, there was a significant improvement in outcome if the brain lesion was ER positive (*P*=0.005), as displayed in [Figure 2](#fig2){ref-type="fig"}, or PR positive (*P*=0.013), but not for HER2-positive lesions (*P*=0.100). In contrast, breast primaries that were ER positive in this group had a trend that was not statistically significant (*P*=0.059) towards an improved overall prognosis. Survival was however significantly improved if there was a longer time from primary diagnosis to the development of brain secondaries (*P*\<0.001).

Discussion
==========

The patients in this study seem to be a reasonably representative cohort in this clinical setting. In a study of breast cancer patients undergoing craniotomy for metastases ([@bib33]), median survival times from brain metastases were identical at 15 months. Initial tumour biology was similar with ER-positive breast tumours in 40% *vs* 37% in this study and HER2 positivity in 45% compared with 32% respectively.

This and other studies have demonstrated changes in the CNS metastases of breast cancer patients. Possible technical explanations for this include simply a natural discordance in assays between the two sets of samples tested. However, at least for the case of ER, there is evidence that multiple simultaneous assays have a low discordant rate of only 3% ([@bib26]). Another possible explanation of variation due to technical reasons is tumour heterogeneity. In this study, by taking three random cores and calculating the mean, the impact of these will be reduced. It was also notable that there was a trend for more positive results in the brain metastases compared with the breast primary for the majority of molecules tested. If there was an element of denaturation of the molecule being tested in the older breast specimens producing a false negative reading, then this trend could result. However, there were high levels of positive levels in the original breast tumour, and with a median time of only 26 months between sampling of the breast and brain tumours, this would seem unlikely to affect the results significantly, even if this was a real phenomenon. Furthermore, there were a number of cases where the opposite occurred, with the brain lesion losing positivity, implying that there is a real change between the primary and secondary tumour. Prospective testing would be required to circumvent this issue fully.

The results of this study suggest that brain metastases are phenotypically very different, and therefore quite possibly biologically different to the breast primary. In many cases, factors linked to drug resistance, metastases or poor prognosis became more evident. Possible explanations for these changes include mutations developing in the original cancer cell or, alternatively, with an original heterogeneous tumour, oncological therapies serving to select out cells with a different, more therapy-resistant biology.

Statistically significant increases in the brain secondaries were seen for p27kip1 and cyclin D1. In the case of p27kip1, downregulation has generally been associated with poorer outcomes, in which case elevated levels in CNS disease might be unexpected. However, one area that raised levels seems to have a detrimental impact is by causing antioestrogen resistance ([@bib71]) that could consequently lead to increased risk of recurrence and metastasis. Cyclin D1 has been linked with a poorer prognosis and can act in collaboration with p27kip1, promoting cell migration ([@bib35]). The fact that both are elevated in this study hints at a possible combination effect in the establishment of CNS metastases. The other significant change in the brain metastases was a reduction in VEGFA. Previous studies have noted a reduction in VEGFA at other sites of metastatic disease ([@bib59]) and an association with a more proliferative nature ([@bib36]), in keeping with the findings of this study.

For current National Institute for Health and Care Excellence (NICE)-approved treatments and their targets, 8 patients had a change to either ER or HER2 (20% of the group) that could have made a difference to their treatment. The question arises as to how much the metastases that have changed to a positive level would benefit from appropriate ER- or HER2-directed therapy. Although this is not clear in this patient group, there is emerging evidence that, overall, HER2-positive brain metastases have superior outcomes with use of HER2-targeted therapy ([@bib24]). The most significant difference for this group in terms of survival time post brain metastasis comparing no treatment with an individual treatment is for chemotherapy and stereotactic brain radiotherapy favouring more intensive treatment. However, there are a multitude of cofounders with potential to affect this, including patient choice, performance status and comorbidities as well as tumour extent and biology.

Previous studies have suggested in general a fall in the hormone sensitivity of breast cancer metastases, including brain metastases ([@bib14]; [@bib3], [@bib4]). This was not the case in this group of patients, with three brain tumours developing ER positivity. Knowing the hormone receptor levels in the brain metastasis appears to give a good indication as to prognosis that in this cohort was stronger statistically than the impact on prognosis with an ER-positive breast cancer. Where they are positive, therapies targeting the hormone pathway become an option. It would therefore seem appropriate to reanalyse tissue obtained from biopsy or resection of a brain metastasis for ER, PR and HER2, with information gathered from this potentially influencing treatment options and guiding prognosis estimation.

In this study, p27kip1, cyclin D1 and VEGFA were significantly altered in brain metastases, with high proportions of brain secondaries developing positivity for p27kip1, cyclin D1, IGF1 and IGF1R. This raises interesting questions into the degree of change and diversity of CNS breast cancer metastases that, in turn, hints at mechanisms for development of such secondaries and possible therapeutic targets. It is however early information in a subset of breast cancer patients who have had little past molecular analysis, and hence there is not a substantial amount of evidence to add to these findings. Regarding impact on clinical outcomes, the changes in p27kip1, cyclinD1 and VEGFA did not have a definite influence on overall prognosis. However, the number of patients in this study means that a moderate effect on clinical outcomes cannot be excluded. Future research could gather more evidence in these areas and eventually trigger development of improved therapies capable of traversing the blood--brain barrier and of activity in the unique microenvironment of the CNS for this poor prognostic group. It would seem appropriate on the basis of results of this study to include investigation of p27kip1, cyclin D1, VEGFA, IGF1 and IGF1R in future work.

Conclusions
===========

In this cohort there were demonstrable phenotypic differences between primary breast cancers and their corresponding brain metastases. In particular, the expression levels of p27kip1 and cyclin D1 were significantly raised in brain metastases, with VEGFA reduced. In addition, EGFR, IGF1 and IGF1R were relatively frequently altered, with the majority becoming positive in the brain metastasis. These changes however did not affect survival time from the diagnosis of the brain secondary.

In all, 20% of patients had a change in ER or HER2 in their brain metastasis that could affect therapeutic decisions. It would seem prudent, therefore, to undertake analysis for these clinical targets if tissue is available from a brain secondary. Patients with a long time from original diagnosis to development of brain metastases and with hormone receptor-positive intracranial lesions had the best outcome. Nevertheless, prognosis is still poor, and much work needs to be done to gain a better understanding of the nature of breast cancer brain metastases to improve therapy and outcomes.
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![(**A**) Photomicrograph of low expression of p27kip1 in a primary breast tumour. IHC × 20. (**B**) Photomicrograph of high expression of p27kip1 in a brain metastasis. IHC × 20.](bjc201634f1){#fig1}

![Kaplan--Meier curve illustrating survival times from the diagnosis of brain metastases according to ER status of the brain secondary.](bjc201634f2){#fig2}

###### Median overall survival from brain metastasis diagnosis in relation to presence or absence of tested molecule in the brain lesion

  **Molecule**    **Positive (+) or negative (**−)  **Median overall survival (months)**
  -------------- ---------------------------------- --------------------------------------
  ER                             \+                 22
                                 −                  6
  PR                             \+                 36
                                 −                  11
  HER2                           \+                 17
                                 −                  10
  EGFR                           \+                 18
                                 −                  17.5
  IGF1                           \+                 13.5
                                 −                  23
  IGF1R                          \+                 7.5
                                 −                  26
  TGF*β*                         \+                 13.5
                                 −                  23
  P27kip1                        \+                 16
                                 −                  9
  Cyclin D1                      \+                 17
                                 −                  6
  VEGFA                          \+                 NA
                                 −                  15
  VEGFR2                         \+                 15
                                 −                  9

Abbreviations: EGFR=epidermal growth factor receptor; ER=oestrogen receptor; IGF1=insulin-like growth factor 1; IGF1R=insulin-like growth factor 1 receptor; NA=not applicable; PR=progesterone receptor; TGF*β=*transforming growth factor-*β*; VEGFA=vascular endothelial growth factor A; VEGFR2=vascular endothelial growth factor receptor 2.

###### Treatment received by patients before and after brain metastasis and impact on times to progression and survival

                                                                                                                                                                                                 **Chemotherapy**  **Hormone therapy**    **HER2-directed therapy**              
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------ --------------------- --------------------------- ------ ---- ----
  **(a) Treatment received by patients before diagnosis of brain metastasis and median time (months) to brain metastasis from breast cancer diagnosis comparing treatment with no treatment**                                                                                    
  0                                                                                                                                                                                                     9          28                                18               21.5   23   23
  1                                                                                                                                                                                                     20         23                                10               27.5   12   26
  2                                                                                                                                                                                                     4                                             6                      0     
  3                                                                                                                                                                                                     2                                             0                      0     
  4                                                                                                                                                                                                     1                                             0                      0     
  Unknown                                                                                                                                                                                               5                                             7                      6     

                                                                                                                                                                                 **Chemotherapy**   **Hormone therapy**   **HER2-directed therapy**              
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------ --------------------- --------------------------- ------ ---- ------
  **(b) Treatment received by patients after diagnosis of brain metastasis and median overall survival (months) from brain metastasis comparing treatment with no treatment**                                                                                    
  0                                                                                                                                                                                     27                  10                       26               13.5   34   16.5
  1                                                                                                                                                                                     6                  33.5                       7               16.5   1     6
  2                                                                                                                                                                                     0                                             1                      0      
  3                                                                                                                                                                                     1                                             0                      0      
  4                                                                                                                                                                                     1                                             0                      0      
  Unknown                                                                                                                                                                               6                                             7                      6      

###### Number and percentage of patients with positive breast cancer and brain metastasis for the molecule tested and changes in profile from breast primary to brain metastasis

                                                         
  ----------- ---------- ---------- --- ------- ---- --------
  ER           15 (37%)   18 (44%)   0   (0%)    3    (12%)
  PR           6 (15%)    7 (17%)    0   (0%)    1     (3%)
  HER2         13 (32%)   17 (41%)   1   (8%)    5    (18%)
  EGFR         24 (59%)   29 (71%)   1   (4%)    6    (35%)
  IGF1         29 (71%)   38 (93%)   3   (10%)   12   (100%)
  IGF1R        37 (90%)   38 (93%)   3   (8%)    4    (100%)
  TGF*β*       40 (98%)   40 (98%)   1   (3%)    1    (100%)
  P27kip1      21 (51%)   31 (76%)   5   (24%)   15   (75%)
  Cyclin D1    18 (44%)   27 (66%)   3   (17%)   12   (52%)
  VEGFA         0 (0%)     0 (0%)    0   (0%)    0     (0%)
  VEGFR2       40 (98%)   40 (98%)   1   (3%)    1    (100%)

Abbreviations: EGFR=epidermal growth factor receptor; ER=oestrogen receptor; IGF1=insulin-like growth factor 1; IGF1R=insulin-like growth factor 1 receptor; NA=not applicable; PR=progesterone receptor; TGF*β=*transforming growth factor-*β*; VEGFA=vascular endothelial growth factor A; VEGFR2=vascular endothelial growth factor receptor 2.
